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John AA Nichols1*, Paul Grob1, Simon de Lusignan1, Wendy Kite2 and Peter Williams3Abstract
Background: A gene-based estimate of lung cancer risk in smokers has been shown to act as a smoking cessation
motivator in hospital recruited subjects. The objective of this trial is to determine if this motivator is as effective in
subjects recruited from an NHS primary care unit.
Method/Design: Subjects will be recruited by mailings using smoking entries on the GP electronic data-base
(total practice population = 32,048) to identify smokers who may want to quit. Smoking cessation clinics based on
medical centre premises will run for eight weeks. Clinics will be randomised to have the gene-based test for estimation
of lung cancer risk or to act as controls groups. The primary endpoint will be smoking cessation at eight weeks and six
months. Secondary outcomes will include ranking of the gene-based test with other smoking cessation motivators.
Discussion: The results will inform as to whether the gene-based test is both effective as motivator and acceptable to
subjects recruited from primary care.
Trial registration: Registered with Clinical Trials.gov, Registration number: NCT01176383.
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Gene testing in primary care is no longer limited by their
exorbitant cost. The prices of genetic tests are dropping
faster than Moore’s law for computing costs [1]. This leads
the focus to shift from cost of genetic testing to the clin-
ical value of individual gene tests. The recent development
of gene-based tests that predicts the risk of lung cancer in
smokers is an important example [2].
Despite the well accepted 10-15% probability of lung
cancer in smokers, 50% of smokers do not believe they are
at significantly increased risk [3]. However, over 80% of
smokers would like to know their personal risk of lung
cancer [4]. There is a plausible three way link between
biomarkers for chronic obstructive pulmonary disease
(COPD), a set of 20 single nucleotide polymorphisms* Correspondence: drjaan@ntlworld.com
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unless otherwise stated.(SNPs) associated with cancer risk and lung cancer [5-8]
(Figure 1). Research has shown a strong association be-
tween a high lung cancer susceptibility score derived
from family history of cancer, the 20 SNPs, COPD history
(Auckland formula) and the development of lung cancers
whereas healthy smokers matched for age, gender and life-
time smoking habits had a relatively low score (n = 446
lung cancer subjects, 484 healthy current smokers). The
odds ratio for lung cancer risk varied from 0.2-3.2 depend-
ing on the genetic risk (p < 0.001) [9,10]. The accuracy of
the Auckland formula in estimating lung cancer risk for a
score of >4 was: sensitivity 90%, specificity 45% (Figure 1
which also includes scores for 52 subjects who developed
cancer from a six year prospective study of 1212 smokers
and ex-smokers). The score for prediction of non-cancer
was conducted with a follow up of just six years. It means
that 45% of non-cancer subjects have a low cancer score
and 55% have some degree of increased score. The 55%
with increased scores have simply not been followed upLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Research that established the respiragene test.
Distribution of the Respiragene score in a cross-sectional study
of 484 control smokers (blue) and 446 with lung cancer (red)
(Total = 930) and from the prospective study of 52 lung cancer cases
(green). Reference [8].
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standing this limitation there is now a 20 SNP gene test
for prediction of lung cancer in smokers under the trade
name Respiragene.
Two case-control studies showed a 5-10% increase in
cessation with a single gene test of small effect [11,12].
A small smoking cessation pilot study using spirometry
results and explanations using the Fletcher-Peto diagram
to explain risk demonstrated that patients find this is an
acceptable method and the quit rate at 12 months was
27% [13]. In a randomised control trial patients were given
either a full explanation of the results of spirometry testing,
including an estimation of lung age or just their forced
expiratory volume in the first second (FEV1), without
explanation (control group). The group of patients who
were given the full explanation had a 7.2% higher quit
rate than the control group [14]. Data from a hospital
outpatient cohort in Auckland suggest a larger increase
in quit rate with Respiragene test and the Auckland for-
mula (Table 1). Subjects, who were current smokers in
the pre-contemplative and contemplative stage, were
randomised into either the test group or control group
and only the test group had the Respiragene test. Coun-
selling and follow-up was done by telephone. Using
Auckland formula to incorporate the results of the
Respiragene test, clinical data and family history a score
ranging 1-12 with associated risk level (moderate risk,
high risk, very high risk) was calculated and explainedto test subjects. Neither group were involved in any for-
mal smoking cessation programme. Indeed, of the 13
subjects that had managed to stop smoking, (28% of the
gene-tested group), 48% quit without any medical as-
sistance and only 52% had nicotine replacement therapy
[15,16]. When compared with previous studies using
telephone counselling alone [17] (Figure 2), there is
a 20-25% improvement in smoking cessation with
the Respiragene test (Table 1). The improvement in
intention to quit increases from 56% before testing to 67%
in smokers with an average smokers risk of lung cancer or
89% in smokers with a high risk of lung cancer [18].
A large hospital trial using Respiragene for calculating
lung cancer susceptibility is currently underway in the
USA [19], but there are no planned UK investigations.
This study fills that gap and uses the NHS framework
for smoking cessation. Other studies have taken place
looking at how lung functioning testing in COPD might
motivate smokers to quit, suggesting that it is feasible to
conduct this sort of study [13,14,20]. This protocol de-
scribes a trial to evaluate a gene-based risk test (using
genetic and clinical data) as a smoking cessation mo-
tivator, in smokers wishing to participate in an NHS pri-
mary care smoking cessation clinic (in the action stage of
change), alongside the usual counselling and prescribing
protocol. It will differ from previous studies using gene
testing as a motivator, however, in that the NHS primary
care counselling and prescribing protocol will include sev-
eral other motivators (CO breath testing, saliva cotinine
testing and intensive counselling) whereas the Auckland
trial, using the same gene test, had none of these. Also,
the method of recruitment will differ in that primary
care subjects will, of necessity, be different from the
Auckland hospital outpatient cohort [15,16].
Research question
Can the Respiragene test combined with an estimation
of lung cancer susceptibility be used to increase the
uptake, adherence to and success rate in an established
smoking cessation programme in subjects who want to
quit in a National Health Service, United Kingdom
(NHS UK) setting?
Hypothesis
Genetic testing and estimation of lung cancer suscepti-
bility should increase “smoking cessation outcomes” at six
months to >30% (or 1.5-2 fold greater than usual care) ir-
respective of the risk scores assigned to subjects [11].
Method/Design
This protocol has been approved by Surrey Research
Ethics Committee at the Royal Surrey County Hospital,
Guildford, Surrey, UK.
Table 1 Respiragene study in Auckland NZ (n = 43)
Cancer susceptibility scale
(compared with normal
lifetime risk)
Cancer susceptibility
score
Estimated
lifetime risk of
lung cancer
Initial
intention
to quit
Proportion that
stopped smoking
at 2-4 weeks
Proportion still
not smoking at
6 months
Expected result for
telephone counselling
(Figure 2)
- - 15% 41% 10-20% 9-12%
Telephone
counselling +
Respiragene test
1-2.3 (10-35% risk) 2.3-6.7
(35-65% risk) 6.7-8
(65%-80% risk)
27 had average
risk score
15% 67% 8/27 (30%) 8 (30%)
16 had high or very
high risk score
30-50% (4-10 times
average risk)
89% 10/16 (63%) 6 (37.5%)
Smoking cessation after Respiragene testing and estimation of lung cancer risk with telephone counselling in a small pilot study in Auckland NZ (n = 43)
compared with expected quit rate.
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Focus groups
A number of focus groups of different aged smokers will be
held to enable them to contribute to the design of the study
2/ Recruitment
Subjects will be recruited from a large general practice
in Surrey (practice population= > 30,000). Smokers aged
20-70 years will be identified from the practice records
and contacted by post by their GP. Patients who reply
stating that they wish to stop smoking will be rando-
mised (stratified randomisation to ensure equivalent age
and gender mix) to two clinics (Figure 3) only one of
which will include the gene-based test. Previous trials of
genetic testing in association with smoking cessation
achieved 83-100% of participants opting for the test de-
pending on the method of recruitment [8,21]. There will
be two mailings with SAEs for recruitment with the aim
of recruiting at least 30 subjects per clinic (see Power
calculations under heading “statistics”). In the first letterTailored on-line support
0ne to one support
Group support
Telephone support
NRT alone
NRT/Bupropion + support
Varenicline + support
0 5
Figure 2 Efficacy of the variety of smoking cessation strategies. Perce
type of quitting (chart from West & Shiffman based on Cochrane review da
Therefore telephone support (Table 1) increases success rate by 6% = 9-12the patient’s GP asks the patient to give permission for
the researcher to contact him/her to ask about taking
part in smoking cessation research (with possible genetic
risk testing) and encloses fact sheet 1 and a stamped ad-
dressed envelope (SAE) for reply.
Mailing 2. The principal investigator mails patient with
Letter 2 to ask him/her if they would like to attend
an 8-week smoking cessation clinic and asks if they
would be willing to have a test for genetic suscepti-
bility to development of lung cancer and encloses
SAE for reply.
Mailing 3. The principal investigator mails Group B
subjects and Group A test-concordant subjects to
confirm dates of the smoking cessation sessions and
full patient information leaflet and consent form
enclosed. The information sheet will be slightly dif-
ferent for group A and B. Non-test concordant sub-
jects within group A will be invited to attend the
practice nurse for smoking cessation.10 15 20
nt increase of success for six months over unaided attempts for each
ta). Totally unaided smoking cessation has a 3-6% success rate.
% quit rate.
Figure 3 Consort 2010 flow diagram for GeTTS recruitment.
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i. Inclusion criteria: Aged 20-70 years, smoking more
than 10 cigarettes daily.
ii. Exclusion criteria: Aged under 20 years or over
70 years, smoking less than 10 cigarettes daily,
history of major depression and other psychiatric
conditions, dementias and serious or terminal illness
(cancers etc.). Patients on warfarin would be
excluded due to interactions between warfarin and
varenicline as varenicline will be used as the modern
treatment of choice for smoking cessation. Patients
who smoke less than 10 cigarettes/day and patients
who did not wish to have a genetic test or do not
wish to take part in a research study will be referred
to the practice nurse for smoking cessation.
4/Smoking cessation clinics
For group A subjects, only subjects who have expressed
an interest in having a genetic test and gene-based esti-
mation of susceptibility to lung cancer in mailing 2 will
be invited to participate (see referral for decliners above).
For group B subjects, all subjects willing to participate are
invited to do so. Uptake into smoking cessation programme(i.e. proportion of invitees who accept invitation and attend
clinic of those mailed invitation) will be recorded. All sub-
jects who attend the first session of the research clinic will
be asked by the principal investigator, JN, to sign a consent
form and will be invited to raise any concerns about the
protocol (as explained in the full information sheet). The
consent form will then be countersigned by JN.
Group A clinics and Group B clinics will be held on
different weekdays at the same health centre premises.
Test Subjects who attend Clinic A will be offered a fact
sheet on the health risks of smoking (including
lung cancer) and the option of the gene-based test
for calculation of lung cancer susceptibility whilst
subjects who attend Clinic B will be given the
same fact sheet on the health risks of smoking (in-
cluding lung cancer) but without any reference to
the gene-based test. The principal investigator will
be responsible for handing out the fact sheets and
administering the gene-based test in Clinic A and for
handing out and explaining the fact sheet in Clinic B.
NHS Surrey’s Smoking Cessation Practitioners will lead
in-house smoking cessation clinics A and B using the
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sion of the principal investigator at the medical centre.
There will be:
 Introductory session which includes a new near
patient test for salivary cotinine (nicotine
metabolite) – trade name SmokeScreen [23].
 At session 2, patients will be given advice on
therapies for smoking cessation. We expect that
most patients will opt for a course of varenicline
and they will be advised to contact their GP for a
prescription.
This is followed by seven more weekly sessions and
a follow-up session at six months (Figure 4). Uptake
and adherence to smoking cessation will be moni-
tored by weekly carbon monoxide exhalation mea-
surements (breath test). The principal investigator
will be involved in clinic A administering the gene-
based test and determining if subjects have COPD
from practice records and history in session 1. Par-
ticipants who are heavy smokers, have a smokers
cough and use a salbutamol inhaler can be judged to
have COPD even if this is not entered in their GP
records (all Group A & B subjects will have spirom-
etry at their 6-month follow-up). Subsequently the
principal investigator will report back to clinic A pa-
tients with estimated lung cancer risks (session 3).
To ensure balance in the control clinic the principal
investigator will also attend Clinic B sessions 2 and 3
(see Figure 5 flow charts).
 At the eight week clinic and the 6-month follow-up
clinic smoking cessation status and carbon mo-
noxide breath test score will be recorded and a feed-
back questionnaire used to assess efficacy of various
components will be administered.Mailing 4. Telephone calls followed by letters to
patients with invitation to 6-month follow-up ses-
sion with NHS Smoking Cessation Practitioners and
the principal investigator when cessation rate will be
assessed and verified by repeating the carbon mon-
oxide breath and salivary cotinine tests.
– for further details see Figure 5: flow chartsFigure 4 Timeline of project.We anticipate good attendance at the eight week free
smoking cessation clinic, as would be expected if it were a
regular NHS smoking cessation clinic but the attendance
at the 6-month follow-up clinic may be more challenging.
We consider this attendance essential and as attendance
will take up an evening of their time, study participants
should be paid for their travel expenses (£20) and will re-
ceive up to three reminders. Group B subjects attending
at the 6-month follow up who have been unable to quit
will be offered the gene-based test at this stage.
Technique for taking the respiragene test
The test requires a Buccal swab and the subjects should
not eat or drink within 15 minutes prior to supplying a
sample (if has eaten or taken a drink within 15 minutes
then rinse mouth with tap water). The nurse taking the
sample should wear latex or plastic gloves and take care to
avoid contact with the buccal swab collection tip to avoid
DNA (deoxyribonucleic acid) contamination. Then:
1. Open buccal swab package at the handle end and
carefully remove the swab.
2. Holding handle end of swab stick, scrape the
collection tip firmly against the inside of the cheek
5-6 times (about 10 seconds), being careful not to
press the plunger that ejects the tip.
3. After taking the sample, eject the swab tip into a
labelled 2 ml microcentrifuge tube by firmly pressing
the plunger at the end of the handle.
4. Complete and affix the sample tube label onto the
microtube. The sample label requires the
anonymised trial code for the subject.
Storage of the respiragene test
After sample collection, tips can be kept at room tem-
perature if they are posted immediately. If storage is
necessary, freeze the tubes containing the tips at -20°C.
Packaging instructions for return of samples to Lab21 Ltd
1. Place absorbent material around the tube and then
place tube in the plastic bag provided with the kit.
Seal the plastic back as per the instructions on the bag
Figure 5 Flow chart for the duration of the trial. a. Flow chart of project from start to week 12. b. Flow chart of project to week 36.
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the shipping box.
3. Seal the box with the security seal supplied.
4. Using the Freepost service provided, send the
samples to: Lab 21, 184 Cambridge Science Park,
Cambridge CB4 0GA.
Patients will be asked to sign a disclaimer form that ex-
plains clearly that this test can only give an estimation of
cancer risk and is a test that is still under development
(one copy of form for investigators and one for patient).Interpretation of result of respiragene test
Lung cancer susceptibility is calculated using the Respi-
ragene test Auckland formula [7]:
Lung cancer score = (number of susceptible genotypes) -
(number of protective genotypes) + 3 (for positive family
history) + 4 (for past history of COPD) + 4 (for age >
60 years old).The laboratory reports include the scores with an ex-
planation of how the scores relate to a risk category
(see Table 1). When the subject is aged <60 years, the re-
port will also include the score and risk category that
would apply if the subject is still a smoker at age 60 years
or over.
Follow-up questionnaires
The questionnaires will be slightly different for groups A
(questionnaire 2a) and B (questionnaire 2b) as only 2a will
contain a direct reference to the gene-based test. Patients
who fail to attend at eight weeks and six months will be
contacted by telephone to remind them to complete their
questionnaires and hand them in to the practice manager.
They are designed to determine which subjects have quit
smoking or cut down and which subjects who have failed
to quit still plan to do so. There is a section that asks about
general motivators and components of the smoking cessa-
tion programme. The subjects will be asked to score these
motivators and smoking cessation aids for their efficacy in
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most identical to a validated questionnaire [24]. There are
also further questions on whether the subject would recom-
mend the Respiragene test to a relative or friend and an
open ended question for subjects to add their own com-
ments about the concept of a test that predicts susceptibil-
ity to lung cancer in a smoker.
Data quality assurance
The study has been designed and will be reported in ac-
cordance with CONSORT (Consolidated Statement of
Reporting Trials) [25]. Data will be controlled in accor-
dance with data protection legislation, institutional pro-
tocols of Sussex NHS Research Consortium, and NHS
policies for research and information governance for en-
suring patient confidentiality [26]. Data will be analysed
in SPSS (Statistical Package for Social Sciences) version
15 using an intention to treat approach.
Outcome measures
Primary endpoint
Comparison of smoking cessation rates (7 day point
abstinence and continuous abstinence) in Clinic A and
Clinic B at 8 weeks and six months.
Secondary endpoints
A. Personal data:
1. Number of smokers still smoking who state that
they still plan to stop.
2. Daily cigarette consumption of those still
smoking.
3. Mean scores for ranking of smoking cessation aids
(gene-based test - Clinic A only, salivary cotinine,
lung cancer facts - controls in Clinic B only and
general counselling from NHS smoking counsellors).B. Analyse questions about whether subjects would
recommend the test to a member of family or a
friend.C. Analyse last (open ended) question using qualitative
research methodology.Statistics
Primary end point
The difference between smoking cessation between
Clinic A and Clinic B will be estimated from the four
week and six month follow up for the primary endpoint
(smoking status confirmed by carbon monoxide breath-
alyser and salivary cotinine tests). If there is the ex-
pected higher rate of smoking cessation for Clinic A
compared with Clinic B, statistical significance will be
demonstrated by the χ2 test.
Since there are, as yet, no case-control studies that com-
pare quit rate following the gene-based test versus quitrate without the test, the expected difference in quit rate
between Clinic A and Clinic B is difficult to estimate. Two
case-control studies showing only a 5-10% increase in
smoking cessation involved just a single gene of small
effect [11,12]. In a randomised control trial patients were
given either a full explanation of the results of spirometry
testing, including an estimation of lung age or just the
FEV1, without explanation (control group). The group of
patients who were given the full explanation had a 7.2%
higher quit rate than the control group. However, data
from Auckland suggest a larger uplift of quit rate with
Respiragene. This can be explained by the superior pre-
dictive power of a 20-gene test combined with clinical his-
tory (personal history of COPD and family history of lung
cancer) to give a rather more impressive estimate of can-
cer risk than anything previously available.
The adequacy of sample size was tested using data
from smoking cessation trials that showed:
 30-40% smoking cessation at 6-months with similar
protocols [27,28].
 A 48% quit rate at 2-4 weeks in subjects with high
and very high lung cancer risk scores but this differ-
ence shrinks to 27% at 6 months.
 Data from Young et al [15,18] (independently
verified by McBride et al [11]) that even being
given an average score for lung cancer
susceptibility increases smoking cessation by
approximately 10%.
Therefore, with a minimum sample sizes of 30 per
group the following calculations based on these estimated
quit rates apply (Table 2). Statistical power of 87.1% is
generally acceptable for publication (for alpha error of
5% - i.e. 5% probability of incorrectly rejecting the null
hypothesis that there is no difference in the percentage
values). For further detailed statistical analysis, refer to
Additional file 1.Secondary outcome measures
Similarly, the significance of secondary endpoints on
intention to stop smoking, cigarette consumption, up-
take of invitation to cessation, adherence to cessation
course and self-reported smoking cessation will be cal-
culated by the χ2 test but the p value for the ranking
scores for information on lung cancer risk and other
smoking cessation aids and motivators will be estimated
from the unpaired student t-test.
The open ended question: “How do you feel now
about having had a genetic test that estimates the prob-
ability that you will develop lung cancer at some future
date?” will have to be analysed by qualitative analysis to
determine the main recurrent themes in responses.
Table 2 Summary of values from which the power of the study are estimated
Control group expected
quit rate as %ge
Respiragene group expected
quit rate as %ge
χ2 calculated from
four-some table
P value
based on χ2
Power
calculations*
8 weeks Sample size
30/30*
70% 94% 5.9 <0.05 79.3%
Sample size
60/60*
11.7 <0.01 96.9%
6 months Sample size
30/30**
35% 52% 1.7 NS 36.5%
Sample size
60/60**
6.2 <0.05 87.1%
*Telephone (alone) quit rate (see Table 1) assumed to be 20%.
**Telephone (alone) quit rate (see Table 1) assumed to be 10-15%.
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Overview
Smoking cessation is one of the most cost effective in-
terventions that can be achieved in primary care [29].
However many smokers are very reluctant to commit
to a smoking cessation programme (precontemplative
and contemplative) and about half of those that attend
for smoking cessation intervention (action stage of
change) are likely to drop out or give up trying. There-
fore, any methodology that increases motivation in
both unmotivated and motivated smokers could be
very valuable. The gene-based test we are offering has
shown promise as a smoking cessation motivator in
precontemplative-contemplative smokers in a hospital
outpatient setting [15,18] and now needs to be tested out
as a motivator for improving adherence in a primary
care smoking cessation clinic using a randomised con-
trolled study.Strengths
The main strengths of this study are that it is being car-
ried out on subjects from a large primary care popula-
tion and should therefore be more representative of the
general population than previous studies recruited from
hospital patients and other special groups. We also have
the advantage of being able to carry out this research
within the established framework of the local stop smok-
ing service.Limitations and assumptions
Although we have estimated, based on previous smoking
cessation work using this gene-based test, that the pri-
mary endpoint will show that having the test improves
quit rate by 20-25%, this was based on a cohort of hos-
pital outpatients in Auckland, New Zealand and subjects
recruited from primary care may respond differently. Al-
though we plan to recruit a minimum of 60 subjects, this
may not be enough to balance unexpected and unknown
confounding factors.What we might find
We aim to recruit a minimum of 60 subjects to random-
ise 30 into group A (test group) and 30 into Group B
(control group). The normal experience in NHS smoking
cessation clinics is a drop-out rate of 40-50% [30-32].
We need, therefore, to attempt to recruit about 120 sub-
jects in order to get a statistically significant result, based
on the assumptions in our power calculations. We may,
however, have underestimated the 6-month quit rate using
the NHS local stop smoking guidelines [22] which typic-
ally involves a multi-interventional programme which in-
cludes combinations of varenicline prescriptions, breath
carbon monoxide monitoring and intensive counselling
giving a quit rate of 70-80% at 6-weeks.There are however
no Surrey data for 6-month quit rate which we assume,
on the basis of similar smoking cessation data to be about
half the 6-week figure [33] ≅ 35%.
An unknown and unpredictable factor, that could
skew results significantly, is the possibility that our
multi-interventional approach could help to reinforce
the health risk message equally for subjects in both groups.
Also, the Auckland study design involved recruitment of
precontemplative-contemplative smokers from a hospital
outpatient setting, compared to this study that will involve
primary care subjects who have volunteered to participate
in a smoking cessation programme (ie smokers in the ac-
tion stage of quitting). This population, therefore, could be
sufficiently different to give unexpected results. However,
the results of this trial will inform as to the acceptability of
this approach as well as its effectiveness.Additional file
Additional file 1: Detailed statistical analysis.Abbreviations
CONSORT: Consolidated statement of reporting trials; COPD: Chronic
obstructive pulmonary disease; DNA: Deoxyribonucleic acid; NHS: National
health service UK; SNP: Single nucleotide polymorphism; SAE: Stamped
addresses envelope.
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